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Gene expression profiling analysis of the
putamen for the investigation of compensatory
mechanisms in Parkinson’s disease
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Abstract
Background: Parkinson’s disease (PD) is affecting 5 million people worldwide, but the response mechanisms of the
striatum are still unclear. Therefore, identification of gene expression alterations in the striatum will greatly assist the
development of novel therapy strategies.
Methods: We performed a comprehensive gene expression analysis in 15 PD patients and 15 normal controls to
identify differentially expressed genes (DEGs) using the expression profile GSE20291 from Gene Expression Omnibus
(GEO). Gene Ontology (GO) analysis and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway enrichment
analysis were used to define functions and pathways altered in PD. Protein-protein interaction network was
constructed to find out the modules with close interactions.
Results: Total715 DEGs including 268 up-regulated and 447 down-regulated genes were obtained. GO functional
enrichment analysis indicated that the genes related with neurons function and cell morphogenesis might be changed
upon PD. KEGG pathway enrichment analysis showed that most of the genes were enriched in the nodes of Gap
junction, calcium signaling pathway, phosphatidylinositol signaling system, long-term potentiation, Alzheimer’s disease
and GnRH signaling pathway. Protein-protein interaction network and module analysis suggested that some apoptosis
related genes, such as PRKCA, CDC42 and BCL2 may play critical roles in striatal neurons growth.
Conclusion: Intrinsic striatal tyrosine hydroxylase interneurons growth may be promoted by changes in several genes
expression and thus reduce the functional excitatory synapses.
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Background
Parkinson’s disease (PD) is a progressive neurodegenera-
tive disorder affecting approximately 1% of the popula-
tion over 60 years in industrialized countries [1]. PD is
characterized pathologically with dopaminergic neurons
degeneration in the substantia nigra with concomitant
reduction of dopamine levels in the striatum, especially
putamen, which lead to motor impairments, including
tremor, rigidity and bradykinesia [2,3] and non-motor
symptoms including pain [4]. Treatments with carbi-
dopa, levodopa, dopamine agonists, monoamine
oxidase type B inhibitors, catechol-O-methyltransferase
inhibitors or amantadine are effective to control symp-
toms in the early stages of PD disease but eventually fail
or are associated with unacceptable side effects [5,6].
Thus, novel diagnosis and treatment strategies are ur-
gently needed to be developed [7].
Recent studies have indicated several compensatory
mechanisms for dopamine loss in the striatum [8]. For
example, depletion of dopaminergic nigrostriatal output
leads to enhanced D2 receptors expression level in the
striatum, which promotes the inhibitory effect of the rest
dopamine in the striatum on the activity of the indirect
pathway and delay manifestations of PD motor symp-
toms [9]. Down-regulation of dopamine transporter cau-
ses decreased dopamine reuptake [10]. Activation of
peroxisome proliferator–activated receptor γ coactivator-
1α (PGC-1α) may result in increased expression of
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nuclear-encoded subunits of the mitochondrial respiratory
chain in the putamen of PD patients with dyskinesias [11]
and block of the dopaminergic neuron loss caused by mu-
tant α-synuclein or the pesticide rotenone [12]. High ex-
pression level of glial cell line-derived neurotrophic factor
(GDNF) is also observed in the putamen of PD patients to
promote intrinsic striatal TH interneuronsas growth [13].
Infusion or viral vector-mediated delivery of GDNF into
the striatum has been associated with significant clinical
benefits [14]. However, the compensatory or response
mechanisms in the putamen of PD patients are not very
clear and underlying therapeutic targets are still needed to
be investigated.
Microarrays which allow to rapidly scanning for candi-
date genes and biomarkers can interrogate in parallel ex-
pression levels of thousands of genes in tissue samples
from patients with PD [15]. In the present study, we
aimed to analyze the expression data from putamen
samples of PD patients and normal control and tried to
offer new insights into the gene changes in the putamen
and potential treatment targets for PD.
Methods
Source of data
We extracted the GSE20291 microarray expression pro-
file from Gene Expression Omnibus (GEO, http://www.
ncbi.nlm.nih.gov/geo/) database based on the Affymetrix
Human Genome U133A Array. A total of 30 samples of
putamen tissue were available, including 15 of PD
patients samples approved by the ethic committee of
the Fourth Affiliated Hospital of China Medical Univer-
sity and 15 pathologically normal controls samples, and
there has no significant differences in the sample ages,
gender, postmortem intervals and PH between the con-
trol group and the PD group [16].
The probe-level data in CEL files were converted into
expression measures and background correction and
quartile data normalization were performed by the ro-
bust multiarray average (RMA) algorithm to obtain the
expression profile data [17]. After deleting the Entrez
Genes with the same probe and averaging the values for
the entrez genes with multiple probes, we obtained
12688 genes of the expression profile for the 35 samples.
Identification of differentially expressed genes (DEGs)
Because the DEGs have more relationship with the de-
velopment of disease, Student’s t-test was used to iden-
tify the DEGs between PD patients and normal controls.
All the genes with p-value < 0.05 were selected as DEGs
for further study.
Functional enrichment analysis
Functional enrichment analysis was performed using
the online tool DAVID (Database for Annotation,
Visualization, and Integrated Discovery) [18]. GO (gene
ontology) terms and KEGG (Kyoto Encyclopedia of Genes
and Genomes) pathways were selected with an ad-
justed p-value less than 0.1 calculated by the Expression
Analysis Systemic Explorer (EASE) test which was imple-
mented in the DAVID tool [19]. Benjamini-Hochberg
method was used to further adjust the p-value [20].
Protein–protein interaction (PPI) network construction
The overlapping clusters were detected by CFinder [21]
based on the Clique Percolation Method (CPM) [22].
For the CPM, a protein complex is defined as a union
with all k-cliques can be reached via a series of adjacent
k-cliques (two k-cliques share exactly k - 1 vertices are
adjacent). Results of CFinder are highly correlated to the
value of the parameter k. Larger values of k correspond
to smaller subgraphs of higher density.
PPI data in Human Protein Reference Database (HPRD)
[23] are experimentally derived and manually extracted
from the literature by expert biologists who read, interpret
and analyze the published data.
In the study, we downloaded PPI data from HPRD on
the website http://www.hprd.org/download. The DEGs
were mapped into the PPI network to find out the mo-
lecular mechanism of the PD from protein-protein inter-
actions. A biological graph visualization tool Cytoscape
software was used to construct the PPI networks [24]. In
the PPI networks, proteins/genes were represented with
nodes, while the interaction derived from experimental
repositories and computational prediction methods be-




We used the Student’s t-test to analyze the microarray
dataset GSE20291 from GEO database in order to iden-
tify the DEGs between PD patients and normal controls.
As a result, 715 genes were screened between PD pa-
tients and normal controls with p-value < 0.05, including
268 up-regulated genes and 447 down-regulated genes.
GO functional enrichment and KEGG pathway enrichment
analysis
GO functional enrichment analysis indicated that 715
DEGs were significantly enriched in 225 GO terms and
the top 15 functional nodes were selected in which 5
functional nodes were related with neuron function,
including neuron development, neuron differentiation,
neuron projection development, neuron projection mor-
phogenesis, and cell morphogenesis involved in neuron
differentiation (Table 1). Furthermore, other 4 functional
nodes having a close relationship with neurons were se-
lected when using p-value < 0.1 as the threshold, including
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neuron projection regeneration, central nervous system
neuron differentiation, central nervous system neuron de-
velopment and neuron recognition. Thus, we suggest that
these abnormal functions of these 9 functional nodes may
be responsible for putamen response for the PD. Subse-
quently, we integrated all the genes in the above 9 func-
tional nodes related with neurons together, containing a
cluster of 40 DEGs, 22 down-regulated genes and 18 up-
regulated genes.
The other important functional nodes in Table 1 were
related with cell morphogenesis, including cell morpho-
genesis, cellular component morphogenesis, cell projec-
tion morphogenesis and cell projection organization.
Our results showed that the nodes related with neurons
had a father-and-son relationship with those nodes re-
lated with cell morphogenesis.
To functionally classify these DEGs in the interaction
network, we performed pathway enrichment analysis by
mapping these genes to KEGG database. The top 6 path-
ways were chosen according to their statistical significance
(Table 2). The enriched pathways included Gap junction,
Calcium signaling pathway, Phosphatidylinositol signaling
system, long-term potentiation, Alzheimer’s disease and
GnRH signaling pathway.
PPI network
In order to mine more important data in the nodes re-
lated with neurons, we constructed the PPI network to
identify more important DEGs and biological modules in
the development of PD. We downloaded protein inter-
action data from HPRD. First, we mapped the genes of
these proteins to Entrez Gene and got 34,180 binary
non-redundant human PPI in HPRD. The number of
genes annotated with at least one interaction was 9,518.
Then we overlapped the genes in Affymetrix Human
Genome U133A Array chip platform to the 9,518 genes
and got a network with 7,670 genes and 31,041 interac-
tions. Next, the 40 genes enriched in the 9 neurons
functional nodes were annotated in the network. We got
735 direct interactions with the 40 genes. Cytoscape
Table 1 Results of functional enrichment analysis for DEGs (top 15)
Term Name Count P-value Adjusted p-value
GO:0032990 Cell part morphogenesis 33 9.58E-09 2.64E-05
GO:0048812 Neuron projection morphogenesis 28 1.04E-07 1.44E-04
GO:0048858 Cell projection morphogenesis 30 1.58E-07 1.45E-04
GO:0032989 Cellular component morphogenesis 40 1.93E-07 1.33E-04
GO:0048667 Cell morphogenesis involved in neuron differentiation 27 2.62E-07 1.45E-04
GO:0031175 Neuron projection development 30 4.04E-07 1.86E-04
GO:0007409 Axonogenesis 25 7.62E-07 3.00E-04
GO:0000902 Cell morphogenesis 36 8.12E-07 2.80E-04
GO:0000904 Cell morphogenesis involved in differentiation 28 1.61E-06 4.93E-04
GO:0030030 Cell projection organization 36 1.76E-06 4.85E-04
GO:0048666 Neuron development 34 2.10E-06 5.27E-04
GO:0030182 Neuron differentiation 40 2.32E-06 5.34E-04
GO:0008285 Negative regulation of cell proliferation 33 2.07E-05 0.004395
GO:0046907 Intracellular transport 49 3.65E-05 0.00717
GO:0031099 Regeneration 12 8.25E-05 0.015071
Count: the number of differentially expressed gene; P-value was obtained by expression analysis systemic explorer test; P-value was adjusted by
Benjamini-Hochberg method.
Table 2 Results of KEGG pathway enrichment analysis for DEGs
Term Name Count P-value Adjusted p-value
hsa04540 Gap junction 14 2.47E-04 0.038054
hsa04020 Calcium signaling pathway 20 5.87E-04 0.045063
hsa04070 Phosphatidylinositol signaling system 11 0.002342 0.059518
hsa04720 Long-term potentiation 11 0.001217 0.061717
hsa05010 Alzheimer’s disease 18 0.001671 0.063516
hsa04912 GnRH signaling pathway 13 0.002101 0.063907
Count: the number of differentially expressed gene; P-value was obtained by expression analysis systemic explorer test; P-value was adjusted by
Benjamini-Hochberg method.
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software was used to display the network graph of 40
genes in the PPI (Figure 1).
In the network, PRKCA, RXRA, CDC42, BCL2, CEBPB,
NOTCH1, GNAO1, SNAP25, PAX6 and VCAN were
located in the central position with degrees of 166,
81, 70, 69, 48, 40, 32, 22, 21 and 19 respectively.
PRKCA had the highest degree among the 10 genes.
The degree of a gene is the number of its neighborhood
genes in PPI network. One gene with high degree, termed
a hub gene, plays a key role in maintaining the inter-
actions between this gene and its neighborhood genes.
The changes of the genes in the central position of
network have more effects compared with those with
smaller degree.
In order to reveal the mechanism of PD, Clique
Percolation Method in cfinder software was employed
to find out the modules with close relationship in the
PPIs network. Under the conditions of K = 3, we got
5 modules. Figure 2 shows one module containing the
most nodes (Figure 2). In the module, 3 DEGs, including
PRKCA (up-regulated), BCL2 (up-regulated) and CDC42
(down-regulated) were involved in the module. PRKCA
with the highest degree had an interaction with all the
other genes in the module.
Figure 1 PPI interactions network of 40 differentially expressed genes related with neurons function. Nodes and links represent human
proteins and protein interactions. Nodes represent the encoding genes of proteins. Red color indicates up-regulated genes annotated in the PPI
network. Blue color indicates the down-regulated genes annotated in the PPI network. Gray color indicates the genes which have interactions
with DEGs.
Figure 2 One module in the PPI network. Nodes indicate
encoding genes of proteins; red color indicates up-regulated genes
annotated in the network; and blue color indicates down-regulated
genes annotated in the network.
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Discussion
In the present study, we analyzed the expression changes
in the putamen of PD patients. A total of 715 genes were
differentially expressed in the putamen of PD patients,
including 268 up-regulated and 447 down-regulated. GO
functional enrichment analysis for these DEGs showed
that the genes related with neuron function and cell
morphogenesis were altered as the disease progressed.
Some studies have shown that a significant (30–50%) re-
duction in spine density in both the caudate nucleus and
putamen of severely dopamine-depleted striata [25].
OPHN1(oligophrenin-1), a Rho-GTPase activating pro-
tein that is required for dendritic spine morphogenesis
was up-regulated in our study as a compensation mech-
anism [26]. Lacking the transcription factor Pax6 has
been associated with defects of tyrosine hydroxylase
(TH)-immunoreactive neurons in the brains [27]. In this
study, Pax6 was also up-regulated and thus intrinsic
striatal TH interneurons might be increased. Intrinsic
striatal TH interneurons, positioned within the striatum
itself, are able to compensatorily produce dopamine
[28,29]. Besides, the nodes of neuron function have
father-and-son relationship with the nodes of cell mor-
phogenesis. This indicates that in the progress of PD,
neurons dysfunction may affect their morphogenesis.
The KEGG pathway enrichment result showed that
these DEGs were significantly enriched in Gap junction,
Calcium signaling pathway, Phosphatidylinositol signal-
ing system, long-term potentiation, Alzheimer’s disease
and GnRH signaling pathway. Gap junctions (GJs) are
found to be expressed in most cell types in the nervous
system, such as neuronal stem cells, neurons, astrocytes,
oligodendrocytes, blood brain barrier cells and micro-
glia/macrophages under inflammatory conditions. Some
studies have shown that phosphorylated gap junction
protein connexin 43 is selectively enhanced in the basal
ganglia regions, which contain dopamine neurons or
their terminal areas (striatum) [30,31]. PD is ameliorated
by Gastrodin by downregulating connexin 43 [32].
Calcium signaling pathway and phosphatidylinositol
signaling system have been demonstrated to be related
with gap junctions. Ca2+ is central to a wide variety of
cellular processes ranging from the regulation of enzyme
activity and gene expression to programmed cell death.
When controlled properly, Ca2+ fluxes through the plas-
ma membrane and between intracellular compartments
are responsible for the fundamental functions of neu-
rons, such as synaptic transmission and plasticity, neu-
rite outgrowth and synaptogenesis, [33]. Studies about
patients, animals and cells have provided large amounts
of data which could confirm that the alterations in Ca2+
regulation are involved in the stroke and chronic neurode-
generative disorders [34]. Calcium-calmodulin-dependent
kinase II (CaMKII), a Ser/Thr kinase, is highly expressed
in the striatum and down-regulation of CaMKII results in
the reduction of functional excitatory synapses and en-
hancement of intrinsic excitability [35]. As expected,
CaMKII was upregulated in this study. Gap junctions can
mediate Ca2+ signals to neighbour cells [36]. Connexin 36
deficiency leads to reduced CaMKII levels in the striatum
and motor behavioral changes [37].
Our PPI network analysis showed that 10 DEGs
(PRKCA, RXRA, CDC42, BCL2, CEBPB, NOTCH1,
GNAO1, SNAP25, PAX6 and VCAN) were hub nodes.
Further module analysis suggested that PRKCA, CDC42
and BCL2 might be more important in the same module
with the same apoptosis or cell cycle function. It has been
reported that PRKCA can be selectively involved in neur-
ite outgrowth and cytoskeletal changes of filamentous
actin and b-tubulin of GT1 hypothalamic neuronal cells
via ERK signal pathway [38]. PRKCA mediates Bcl2 phos-
phorylation and accounts for the increased cell survival
observed following chemotherapy [39]. Inhibition of
PRKCA leads to a decrease in Bcl-xL gene expression and
consequent induction of apoptosis [40].
Cdc42, a Rho-related member of the Ras superfamily,
acts as a GTP-binding protein/molecular switch to con-
trol a diversity of cellular processes. Earlier biochemical
studies in neuronal cells have shown that Cdc42, along
with Rac1, is a positive regulator, whereas RhoA func-
tions as a negative regulator in neurite initiation, axon
growth and branching, and spine formation [41]. In par-
ticular, Cdc42 plays a key role in oligodendrocyte diffe-
rentiation and in neuronal polarity/axon outgrowth and
neuronal migration. In our analysis, Cdc42 is downregu-
lated [42-44]. These results have suggested that lower
Cdc42 may promote phagocytosis of degenerating dopa-
minergic neurons in vivo in PD patients [42].
BCL2 is a major regulator of neural plasticity and cel-
lular resilience. Recent findings have indicated that inter-
action between Bcl-2 and inositol 1,4,5-trisphosphate
(IP3) receptor Ca2+ channels on the endoplasmic reti-
culum could inhibitIP3-mediated Ca2+ signals to induce
neuron apoptosis and enhance Ca2+ signals to support
neuron cell survival [45,46]. The concentrations of Bcl-2
in the nigrostriatal dopaminergic regions are significantly
higher in parkinsonian patients than those in controls
[47], which was also confirmed in our study.
Conclusion
In conclusion, our results suggest that in response to
dopamine deprived in the striatum of PD patients, ex-
pressions of several genes are changed (OPHN1, Pax6,
connexin 43, CaMKII, PRKCA, CDC42 and BCL2) and
these genes may play important roles in promoting in-
trinsic striatal TH interneurons growth and inhibit its
apoptosis. However, further experiments are still needed
to confirm the results of our study.
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